Medpace (NASDAQ:MEDP) Releases Earnings Results, Beats Estimates By $0.40 EPS

Medpace (NASDAQ:MEDP) released its quarterly earnings results on Wednesday. The company reported $4.84 earnings per share for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40, FiscalAI reports. The business had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. Medpace’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the company posted $3.86 EPS.

Medpace Stock Performance

Medpace stock opened at $662.48 on Thursday. The firm has a market cap of $18.49 billion, a PE ratio of 36.49, a P/E/G ratio of 2.78 and a beta of 1.18. The firm’s 50 day moving average price is $608.40 and its two-hundred day moving average price is $535.64. Medpace has a twelve month low of $373.00 and a twelve month high of $677.90.

Insider Transactions at Medpace

In other Medpace news, CEO August Troendle sold 21,966 shares of Medpace stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the completion of the sale, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. This trade represents a 6.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 336,140 shares of company stock valued at $208,008,328. 20.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MEDP has been the subject of several recent analyst reports. Truist Financial raised their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Barclays lifted their price target on Medpace from $600.00 to $625.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Finally, Weiss Ratings raised Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $607.73.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported third-quarter adjusted earnings of $4.84 per share, exceeding analyst estimates of approximately $4.44-$4.45 and rising from $3.86 a year earlier. Revenue increased 8.5% year over year to $716 million, also slightly above expectations. Medpace Holdings Profit Climbs in Q3
• Positive Sentiment: Margin expansion was a key earnings driver, helping produce the 8.5% EPS beat despite relatively moderate revenue growth. Medpace also reported a 17.67% net margin and 110.15% return on equity. Medpace Q3 2026 Margin Expansion
• Positive Sentiment: Management provided 2026 earnings guidance above Wall Street expectations, reinforcing the view that profitability can remain strong. Medpace 2026 Earnings Guidance
• Positive Sentiment: The board authorized a $1 billion share buyback, which could support per-share earnings and signal confidence in Medpace’s valuation and cash-generation prospects. Medpace $1 Billion Buyback and Third-Quarter Profit
• Neutral Sentiment: Although the quarterly results and outlook were strong, reports noted that the shares initially slipped after the release, indicating that investors may have been seeking stronger revenue growth or additional detail on the outlook. Medpace Slips Despite Third-Quarter Beat

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.